Q2 EPS Forecast for Arcturus Therapeutics Lowered by Analyst

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Analysts at HC Wainwright cut their Q2 2026 EPS estimates for shares of Arcturus Therapeutics in a research report issued on Wednesday, May 13th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of ($0.99) for the quarter, down from their previous forecast of ($0.82). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for Arcturus Therapeutics’ Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.88) EPS, FY2026 earnings at ($3.78) EPS, FY2027 earnings at ($3.45) EPS, FY2028 earnings at ($2.99) EPS, FY2029 earnings at ($3.95) EPS and FY2030 earnings at ($4.42) EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.08. The company had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%.

ARCT has been the topic of several other research reports. Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, April 21st. Roth Mkm started coverage on Arcturus Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 target price for the company. Piper Sandler dropped their price target on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Citigroup cut their price target on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Finally, B. Riley Financial began coverage on Arcturus Therapeutics in a report on Wednesday, March 18th. They issued a “buy” rating and a $22.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $25.44.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $7.83 on Friday. The company has a 50 day moving average price of $7.91 and a 200-day moving average price of $7.57. Arcturus Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $24.17. The company has a market capitalization of $222.53 million, a PE ratio of -2.79 and a beta of 2.43.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of ARCT. ARK Investment Management LLC increased its holdings in shares of Arcturus Therapeutics by 39.4% in the 4th quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after acquiring an additional 738,378 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Arcturus Therapeutics by 12.9% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,671,000 after acquiring an additional 262,347 shares in the last quarter. Amova Asset Management Americas Inc. lifted its stake in shares of Arcturus Therapeutics by 12.9% during the 1st quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after purchasing an additional 262,347 shares during the last quarter. Vanguard Group Inc. boosted its position in Arcturus Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock valued at $34,752,000 after purchasing an additional 75,440 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Arcturus Therapeutics by 112.0% during the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after purchasing an additional 327,626 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.